It takes an ecosystem to build a startup and world class innovation to build a good biotech company. And to develop a scientific discovery into a life-changing drug or technology, it takes experts from various fields. All of this and more can be found nestled between the borders of France and Germany, namely, in the Basel Area in Switzerland.
Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories! .
"We are building the Next Generation of Digital Media for Biotech"
Philip, Joachim and the growing team at Labiotech.eu
Biomarker Technologies Market by Profiling Technology (Chromatography, NGS, PCR, Mass Spectrometry, Immunoassay, Liquid Biopsy (ddPCR, DHPLC)), Research Area (Proteomics, Lipidomics), Application (Biomarker Validation, Biomarker Discovery) - Global Forecast to 2022
Efficacy Testing Market by Product and Service (Consumables, Services), Type (Antimicrobial Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharmaceutical Manufacturing, Cosmetic & Personal Care Products) - Global Forecast to 2022
Oncology Nutrition Market by Cancer Type (Head & Neck, Stomach & Gastrointestinal, Liver, Pancreatic, Esophageal, Lung, Breast, Blood) - Global Forecast to 2023
Oncology Information System Market by Software (Patient Information System & TPS), & Professional Service), Application (Medical, Radiation, & Surgical Oncology), End User (Hospital, Government Institution, & Research Center) - Global Forecasts to 2019
Non Invasive Prenatal Testing (NIPT) Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021
Bioinformatics Market by Product & Service (Knowledge Management Tools, Data Analysis Platforms (Structural & Functional), Services), Applications (Genomics, Proteomics & Metabolomics), & Sectors (Medical, Academics, Agriculture) - Global Forecast to 2023
Hepatitis C Increases Diabetes Risk in Kidney Transplant Recipients
OCTOBER 22, 2018Jared Kaltwasser
Alzheimer’s can occur in 30s & 40s: Common signs include repeating questions, becoming suspicious of others
ET CONTRIBUTORS|Oct 23, 2018, 03.00 PM IST
By Dr Kalyani Karkare
IN THE JOURNALS PLUS
Diabetes prevalence reaches 9.7% of U.S. population in 2016 and 2017
October 22, 2018
An estimated 8.5% of the U.S. adult population was diagnosed with type 2 diabetes and 0.5% was diagnosed with type 1 diabetes in 2016 and 2017, according to a study published in BMJ.
In addition, adults with type 2 diabetes made up 91.2% of the U.S. population with some form of diabetes, whereas 5.6% of the population with diabetes had type 1.
Even more evidence finds link between herpes virus and Alzheimer’s
September 2018 -
We see a growing disconnect between waning market attention to our top 10 geopolitical risks and the likelihood of some of them escalating. Our global BlackRock Geopolitical Risk Indicator (BGRI) has declined since our last update, suggesting the market’s attention to geopolitical risks overall has edged down. Yet the overall reading masks considerable dispersion, and we have raised the likelihood of three of our risks.Global trade tensions is our focus risk this month as U.S. trade disputes with major trading partners carry on.
Sep 19, 2018 - By Russ Koesterich
At $3.5 trillion per year, total healthcare spending (public and private) makes up roughly 20% of the U.S. economy. The nation’s 80 million baby boomers provide a stable source of ongoing revenue growth for healthcare companies throughout the value chain. Demographic tailwinds are widely expected to continue to propel this secular story in the United States.
Sep 14, 2018 By Michael Fredericks
In the United States, we continue to observe above-trend fundamental data, including strong corporate earnings, capital expenditures (business investment) and consumer sentiment. U.S. stocks notably outperformed international markets, with the S&P 500 Index rallying over 3% in August whereas European equities, for instance, were negative. We believe U.S. outperformance will likely persist in the near-term, underscoring our preference for more domestic-oriented assets.
Oct 1, 2018
We see the steady global expansion rolling on, underpinned by above-trend U.S. growth. Yet the range of potential economic outcomes is widening. Gradual increases in U.S. rates are tightening financial conditions globally, and have contributed to bouts of volatility and sharply depreciating emerging market (EM) currencies. We also take a deep dive into the prospects for EMs after an unexpectedly drawn-out selloff.
Oct 8, 2018 By Richard Turnill
Global equities’ nearly decade-long bull run is stoking anxiety about its ability to power on. One concern: narrow breadth — a fragile state when a small group of stocks is contributing the lion’s share of market returns, buoying the broader index. We see today’s strong equity performance, especially in the U.S., as broad-based and driven by healthy fundamentals and solid earnings momentum.
Increasing number of surgical procedures is driving the surgical instruments market
The global genomics market size is expected to reach USD 27.6 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 9.7% during the forecast period.
Published Date: Sep, 2018
Metagenomics Market Size, Share & Trends Analysis Report By Product (Sequencing & Data Analytics), By Technology (Sequencing, Function), By Application (Environmental), And Segment Forecasts, 2018 - 2025
Some of the prominent players operating in this market are Illumina, Inc.; Promega Corporation; Novogene Corporation; Oxford Gene Technology, Inc.; Thermo Fisher Scientific, Inc.; TAKARA BIO INC.; Danaher; QIAGEN; and ELITechGroup.
Washington, D.C. (September 11, 2018)
Small Business Optimism Shatters Record Previously Set 35 Years Ago
The NFIB Small Business Optimism Indexsoared to 108.8 in August, a new record in the survey’s 45-year history, topping the July 1983 highwater mark of 108. The record-breaking figure is driven by small business owners executing on the plans they’ve put in place due to dramatic changes in the nation’s economic policy.
Every cancer, like every patient, is different. Genomic tumor assessments help identify the DNA alterations that are driving the growth of a particular tumor. As we understand more about these gene mutations, we are better able to provide cancer treatment therapies that specifically target changes in the tumor's genomic profile. Information about genomic changes that are unique to your individual cancer may help us determine treatments that may be appropriate for you. It's the promise of precision cancer treatment—a focus on the individual tumor in the individual patient.
Feb 23, 2018 at 12:29PM
Top DNA Stocks to Consider Buying
Thanks to tremendous advancements in genomic sequencing and the development of gene editing techniques like zinc-finger nuclease and CRISPR (clustered regularly interspaced short palindromic repeats), scientists now have the tools and know-how to make changes to our genetic code like never before.
The NFIB Small Business Optimism Index continued its historic 23-month positive trend, with a reading of 107.9 in September, the third highest reading in the survey’s 45-year history. In the small business half of the economy, 2018 has produced 45-year record high measures of job openings, hiring plans, actual job creation, compensation increases (actual and planned), profit growth, and inventory investment.
The NFIB Research Foundation has collected Small Business Economic Trends data with quarterly surveys since the 4th quarter of 1973 and monthly surveys since 1986. Survey respondents are drawn from NFIB’s membership. The report is released on the second Tuesday of each month. This survey was conducted in September 2018.